You are here: Industry Insights > osteoarthritis

News List

FDA Approves Monoclonal Antibody to Treat Arthritis in Cats drugs.com
January 13, 2022
Arthritis can keep a cat from doing many of the things that kitties love to do. But now there's hope: The first treatment to ease arthritis pain in cats has been approved by the U.S. Food and Drug Administration.
Grünenthal Acquires Mestex AG and it's Phase-III-Ready Investigational Medicine MTX-071 for the Treatment of Pain Associated with Osteoarthritis of the Knee americanpharmaceuticalreview
April 13, 2021
Grünenthal has announced the acquisition of Mestex AG through the takeover of all of its shares and options. Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the ...
TissueTech Receives FDA Clearance for TTAX03 Study to Treat Facet Joint Osteoarthritis Pain americanpharmaceuticalreview
March 12, 2021
Amniox Medical announced its parent company TissueTech had received clearance from the U.S. Food and Drug Administration (FDA) to proceed with a dosing study using its Investigational New Drug (IND) TTAX03 to treat facet joint pain resulting from OA.
Lupin launches Meloxicam Capsules expresspharma
December 29, 2020
Lupin announced the launch of Meloxicam Capsules, 5 mg, and 10 mg, having received an approval from the United States Food and Drug Administration (US FDA).
Merck KGaA out-licenses osteoarthritis programme to Novartis pharmatimes
October 10, 2020
Germany’s Merck KGaA has entered into an out-licensing agreement with Novartis for the development of an osteoarthritis clinical-stage programme.
NSAIDs Contribute to Increased CVD Risk in Osteoarthritis drugs
August 09, 2019
Osteoarthritis (OA) is an independent risk factor for increased cardiovascular disease (CVD), and nonsteroidal anti-inflammatory drugs (NSAIDs) contribute substantially to this risk...
Tanezumab Improves Scores for Pain, Function in Osteoarthritis drugs
July 04, 2019
Tanezumab Improves Scores for Pain, Function in Osteoarthritis.
GSK and Novartis ‘misled’ consumers, says Federal Court of Australia europeanpharmaceuticalreview
May 21, 2019
GSK and Novartis found to have misled consumers with the packaging and pricing of their osteoarthritis pain treatment.
Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial pharmaceutical-business-review
April 23, 2019
Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).
American Academy of Orthopaedic Surgeons, March 12-16 drugs
March 20, 2019
The annual meeting of the American Academy of Orthopaedic Surgeons was held from March 12 to 16 in Las Vegas and attracted approximately 30,000 participants from around the world.

Previous page 1 2 Next page